Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Application of rapidly prepared nonactivated high-efficiency chimeric antigen receptor T cells in the treatment of bladder cancer.

Created on 30 Oct 2026

Authors

Guojing Pei, Yanjie Liang, Wen Zhang, Mengru Kang, Kang Du, Dongqi Tang, Zhen Zhang, Fang Xiao

Published in

Current urology. Volume 20. Issue 6. Pages 379-391. Epub Mar 03, 2026.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is clinically limited by lentiviral vector dependence, ex vivo activation/expansion requirements, complex processes, high costs, and impaired antitumor functions. For advanced cancer, the long manufacturing cycle of traditional CAR-T cells further compromises the treatment timeliness, creating an urgent need for optimized preparation strategies.
A gene delivery system was constructed using microtubule-associated sequence and nuclear localization signal peptide-modified poly(β-amino ester) nanoparticles, combined with microfluidic technology. Nonactivated primary human T cells were transfected without ex vivo activation. The transfection efficiency, gene expression persistence, and in vitro cytotoxicity against the B7-H3-positive bladder cancer cell line T24 were evaluated.
The system achieved gene delivery to nonactivated T cells within 2 to 6 hours, with a transfection efficiency that was 7-fold higher than that of unmodified nanoparticles. Target genes were stably expressed for over 5 days. The resulting CAR-T cells exhibited potent, specific cytotoxicity against T24 cells, avoiding viral vector risks and reducing manufacturing costs.
This strategy innovates CAR-T-cell preparation by targeting nonactivated T cells and overcoming traditional bottlenecks. This provides a simpler, faster, cost-effective, and safe approach for adoptive cellular immunotherapy with significant translational value for bladder cancer and other solid tumors.

PMID:
42960358
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement